Cue Biopharma (NASDAQ:CUE) VP Sells $169,346.52 in Stock

Cue Biopharma, Inc. (NASDAQ:CUE) VP Michael Vincent Meluzio sold 5,628 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $30.09, for a total value of $169,346.52. Following the transaction, the vice president directly owned 48,961 shares in the company, valued at approximately $1,473,236.49. This represents a 10.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cue Biopharma Stock Performance

NASDAQ:CUE opened at $26.28 on Thursday. The stock’s fifty day moving average is $29.34 and its 200 day moving average is $139.45. Cue Biopharma, Inc. has a fifty-two week low of $4.97 and a fifty-two week high of $45.50. The firm has a market capitalization of $110.38 million, a PE ratio of -0.97 and a beta of 2.47.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings data on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing the consensus estimate of ($1.69) by ($22.45). Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%.The firm had revenue of $7.88 million for the quarter, compared to analysts’ expectations of $3.00 million.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cue Biopharma in a report on Thursday, August 13th. Wall Street Zen downgraded shares of Cue Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday, August 15th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Hedge Funds Weigh In On Cue Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. grew its stake in Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after buying an additional 73,000 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Cue Biopharma during the third quarter valued at about $62,000. Stifel Financial Corp raised its position in shares of Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock valued at $75,000 after purchasing an additional 50,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc raised its position in shares of Cue Biopharma by 1,231.2% in the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock valued at $135,000 after purchasing an additional 407,568 shares during the last quarter. Finally, Boothbay Fund Management LLC boosted its stake in Cue Biopharma by 15.3% in the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares in the last quarter. 35.04% of the stock is owned by hedge funds and other institutional investors.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.